Go Deep
Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 18,124 | -11.2 | 6.44 | 0.28 | 711.16 |
| Oct 2026 | 18,075 | -11.3 | 6.48 | 0.28 | 716.01 |
| Oct 2026 | 18,424 | -11.6 | 6.17 | 0.28 | 680.05 |
| Oct 2026 | 18,889 | -10.8 | 5.76 | 0.28 | 635.27 |
| Oct 2026 | 17,667 | -12.8 | 6.84 | 0.28 | 754.74 |
| Oct 2026 | 17,463 | -13.2 | 7.02 | 0.28 | 772.74 |
| Oct 2026 | 17,163 | -13.7 | 7.29 | 0.28 | 800.43 |
Cumberland Pharmaceuticals Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 166,458.0 | 9,131,317.0 | 13,678,651.0 | 8,292,362.0 |
| Net Profit | -4,276,377.0 | -3,289,639.0 | -1,411,692.0 | -1,940,764.0 |
| EPS | -0.3 | -0.2 | -0.1 | -0.1 |
Cumberland Pharmaceuticals Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 44,521,431.0 | 37,867,945.0 | 39,552,507.0 | 42,010,949.0 | — |
| Net Profit | -2,836,128.0 | -6,479,770.0 | -6,279,320.0 | -5,570,241.0 | — |
| EPS | -0.2 | -0.5 | -0.4 | -0.4 | — |
Cumberland Pharmaceuticals Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 76,823,992.0 | 75,583,410.0 | 81,776,075.0 | 92,925,158.0 | — |
| Total Liabilities | 52,279,770.0 | 53,037,433.0 | 52,516,206.0 | 56,951,152.0 | — |
| Total Equity | 24,880,322.0 | 22,853,494.0 | 29,603,441.0 | 36,266,132.0 | — |
Owes vs Owns
Cumberland Pharmaceuticals Inc. owed $0.73 for every $1 it owned in Jun 2026, up from $0.61 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.73× | 0.68× | 0.70× | 0.64× | 0.61× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Cumberland Pharmaceuticals Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 14.9%Receivables 22.1%Inventory 8.1%Fixed assets (tangible) 11.2%Intangible assets 19.4%Long-term investments 5.2%Other assets 19.1%
How it's funded — Dec 2025
Short-term debt 0.6%Long-term debt 6.8%Payables 24.2%Other liabilities 36.5%Shareholders' equity 31.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 11.4 | 18.0 | 18.3 | 19.8 |
| Receivables | 16.9 | 11.7 | 9.8 | 13.2 |
| Inventory | 6.2 | 4.0 | 4.6 | 9.9 |
| Fixed assets (tangible) | 8.6 | 6.5 | 7.0 | 5.5 |
| Intangible assets | 14.9 | 18.9 | 23.5 | 31.5 |
| Long-term investments | 4.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 14.7 | 16.6 | 18.5 | 13.1 |
| Liabilities & equity | ||||
| Short-term debt | 0.5 | 5.1 | 0.3 | 0.2 |
| Long-term debt | 5.2 | 10.2 | 12.8 | 16.2 |
| Payables | 18.6 | 13.9 | 14.0 | 10.8 |
| Other liabilities | 28.0 | 23.8 | 25.3 | 29.8 |
| Shareholders' equity | 24.5 | 22.5 | 29.3 | 36.0 |
| Net tangible assets | 9.9 | 4.0 | 6.1 | 4.8 |
Cumberland Pharmaceuticals Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 4,932,522.0 | -612,186.0 | 6,093,821.0 | 8,453,396.0 | — |
| Investing Activities | -4,706,497.0 | 57,842.0 | -105,695.0 | -13,674,456.0 | — |
| Financing Activities | -6,745,516.0 | 196,904.0 | -7,424,472.0 | -2,061,786.0 | — |